5535.0000 -31.00 (-0.56%)
NSE Dec 26, 2025 15:31 PM
Volume: 40,414
 

5535.00
-0.56%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Alkem Laboratories Ltd. is trading below its 30 day SMA of 5647.3
More from Alkem Laboratories Ltd.
Recommended